Dermatologists have many years of experience with the tumor necrosis factor-alpha (TNF-α) inhibitors Humira (AbbVie) and Enbrel (Pfizer) as first-line biologics for the treatment of psoriasis…
The lucrative EU5 rheumatoid arthritis market is dominated by biologics, including five tumor necrosis factor (TNF)-α inhibitors and four biologics with alternative mechanisms of action. The TNF…
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that usually affects children but can persist or start in adulthood. For many years, the treatment landscape has remained…
The tumor necrosis factor (TNF) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. However, several…
IBS-D is a highly prevalent disorder regularly encountered in general practice that is marked by excessive defecation and abdominal pain/discomfort. Currently, its etiology and pathophysiology are…
Gram-negative infections (GNIs) account for a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these…
Incyte/Novartis’s Jakafi/Jakavi (ruxolitinib) is the first and only drug approved for MF in the United States (2011) and EU5 (2012). While Jakafi/Jakavi offers a therapeutic option for patients…
Abstract: The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis factor alpha (TNF-α)…
Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used throughout the course of disease…
Treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…
MARKET OUTLOOK The U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets include the predominantly entrenched TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira…
In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of…
AD is a chronic inflammatory skin disease marked by pruritus, eczema, and, in moderate to severe patients, frequent relapse. Standard AD treatments aim to protect the skin barrier through…
In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S…
Although TNF-α inhibitors and other RA biologics are generally considered efficacious and safe and adequately control disease in many conventional DMARD-refractory RA patients, therapies that are…